News

Today, March 6, 2023, is the last day of trading with the warrants of series TO13B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO13B runs up until March 8, 2023. Each warrant...

iZafe Group AB ("iZafe Group") hereby announces that the company has signed an exclusive collaboration agreement with Targeted Outcomes for the rights to sell and market the pharmaceutical robot Dosell in the United Kingdom for a period of 5...

iZafe Group AB ("iZafe Group") announce that it has signed an exclusive partnership agreement with IVE Ventures (“IVE”) for the right to exclusively sell and market the Dosell medication robot in the Netherlands. IVE has committed...

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate...

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and...

iZafe Group (publ.) hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden. The municipalities, which together have approximately 13,500 residents aged 65 and over, initially...

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment...

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser. Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified...

iZafe Group AB (publ) ("iZafe" or the "Company") has today entered into a share purchase agreement with the owners of Pilloxa AB ("Pilloxa") regarding the acquisition of all outstanding shares of Pilloxa in accordance with...

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers. “iZafe and the medicine robot Dosell...

iZafe Group AB (publ.) - presents today, November 7, its report for the third quarter of 2022. Summary of financial performance Significant events during the quarter Significant events after the end of the quarter COMMENTS FROM THE CEO A lot has happened...

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with Medcam AB, which sells medical technology products to healthcare in the Nordics and Europe. In the first place, the focus will be on the Dutch market, but the company...

iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were...

iZafe Group AB (publ.) announces today that it is starting a pilot project with Aleris. The aim of the project is to produce decision-making material for a potential introduction of the pharmaceutical robot Dosell in Aleris for the patient group advanced...

iZafe Group (publ.) hereby announces that the partner Remedio has sold its concept to 12 pharmacies which in a short time have 2,000 active customers who receive their medicines in sachets. "Getting the medicine in sachets is completely new to the...

Today, October 7, 2022, is the last day of trading with the warrants of series TO10B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO10B runs up until October 11, 2022. Each warrant...

iZafe Group (publ.) hereby announces that two municipalities in Sweden are choosing to implement Dosell now in October. "We see an increased demand from municipalities that wish to implement Dosell, the period for implementation is short before the...

Members of the Board of Directors, management team and the incoming Chairman of the Board of iZafe Group AB ("iZafe" or the "Company") exercise all held warrants of series TO10B. The number of warrants of series TO10B that the Board...

iZafe Group (publ.) hereby announces that the partner Hepro AS is now starting the implementation of 25 Dosell units in a municipality in the western region of Norway. The municipality, which has approximately 3,300 residents aged 65 and over, initially...

iZafe Group (publ.) hereby announces that the partner Careium AS is now starting the implementation of 20 Dosells in a municipality in eastern Norway. The municipality, which has approx. 5,171 residents aged 65 and over, will initially start with 20 Dosells...

iZafe Group AB ("iZafe" or the "Company") issued, in connection with a rights issue in the fourth quarter of 2021, warrants of series TO10B. Each warrant gives the right to subscribe for one (1) new share of series B in the Company...